Author

T. K. Schramm

Observed names: T SCHRAMM, T Schramm, T.K. Schramm, TK Schramm

Observed institutions: University of Copenhagen, German Sport University Cologne, Amager Hospital, Frederiksberg Hospital, Bispebjerg Hospital, Gentofte Hospital, Rigshospitalet

OpenAlex ID: A5110036352

Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Among Healthy Individuals: A Nationwide Cohort Study

2008 · EL Fosbøl, GH Gislason, et al. · Clinical Pharmacology & Therapeutics · 197

Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study

2010 · C. Andersson, J. B. Olesen, et al. · Diabetologia · 153

PDF

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

2023 · PK Judge, N Staplin, et al. · The Lancet Diabetes & Endocrinology · 148

PDF

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

2023 · N Staplin, R Haynes, et al. · The Lancet Diabetes & Endocrinology · 125

PDF

Cardiovascular safety of combination therapies with incretin‐based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus – a retrospective nationwide study

2014 · U. M. Mogensen, C. Andersson, et al. · Diabetes Obesity and Metabolism · 54

Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction—a nationwide study

2010 · M. L. Norgaard, S. S. Andersen, et al. · Diabetologia · 53

PDF

Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study

2009 · S. S. Andersen, M. L. Hansen, et al. · EP Europace · 38

PDF

Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension

2001 · HG Predel, W Mainka, et al. · Journal of Human Hypertension · 37

'Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study'

2012 · T. K. Schramm, G. H. Gislason, et al. · European Heart Journal · 31

Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers

2008 · M. L. Hansen, N. Gadsboll, et al. · EP Europace · 24

PDF

Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction — A nationwide study

2010 · C.H. Jørgensen, G.H. Gislason, et al. · International Journal of Cardiology · 22

Initiation and Persistence to Statin Treatment in Patients with Diabetes Receiving Glucose-Lowering Medications 1997- 2006

2009 · H. Dominguez, T. K. Schramm, et al. · The Open Cardiovascular Medicine Journal · 19

PDF

Clinical consequences of hospital variation in use of oral anticoagulant therapy after first‐time admission for atrial fibrillation

2009 · M. L. Hansen, N. Gadsbøll, et al. · Journal of Internal Medicine · 4

PDF

DPP-4 inhibitors and GLP-1 agonists in type 2 diabetes - early assessment of cardiovascular safety in a nationwide setting

2013 · U. M. Mogensen, C. Andersson, et al. · European Heart Journal

Differences in mortality and cardiovascular risk associated with insulin in combination with individual insulin secretagogues or metformin - a nationwide study

2013 · U. M. Mogensen, C. Andersson, et al. · European Heart Journal

445 Poor compliance with pharmacological treatment in chronic heart failure identifies high-risk patients and is associated with increased mortality

2007 · G GISLASON, J RASMUSSEN, et al. · European Journal of Heart Failure Supplements

533 Underuse of ACE inhibitors, beta-blockers and spironolactone in patients with heart failure is primarily due to lack of initiation of treatment

2006 · G GISLASON, J RASMUSSEN, et al. · European Journal of Heart Failure Supplements

Amlodipin im Study Program on Physical activity and on Risk reduction in Treated Hypertensives (SPORT-H) - hämodynamische, metabolische und hormonale Effekte bei körperlich aktiven Patienten mit arterieller Hypertonie

2001 · T. K. Schramm, HG Predel, et al. · Journal für Kardiologie (Krause & Pachernegg GmbH)

PDF

G004 Plasma leptin levels in patients with essential hypertension - modulatory effects of maximal and submaximal exercise

1998 · T SCHRAMM · American Journal of Hypertension

D124 Integrated cardio-pulmonary and metabolic effects of the CA-channel-antagonist (CAA) amlodipine in physically active patients with essential hypertension (EH)

1997 · T SCHRAMM · American Journal of Hypertension

Works count: 20

Citation count: 905

H-index: 12

I10-index: 12